Log in to search using one of your social media accounts:

 

Kaleo launches program to get Auvi-Q allergy auto-injector into schools

Kaleo said today that it launched a new program to offer its epinephrine auto-injector, Auvi-Q, free-of-charge to all public elementary schools in the U.S. The program is slated to give up to four Auvi-Q cartons per school each academic year. Each carton has two auto-injectors and a training device. Get the full story at our sister site, Drug Delivery Business News. The post Kaleo launches program to get Auvi-Q allergy auto-injector into schools appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Pharmaceuticals Respiratory Kaleo Inc Source Type: news

Related Links:

We take a look at the health effects of the common mold Cladosporium, the associated symptoms it can cause, and some removal tips.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Allergy Source Type: news
We take a look at the health effects of the common mold Cladosporium, the associated symptoms it can cause, and some removal tips.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Allergy Source Type: news
Conclusions Looking at this selected population, we suggest that mastocytosis should be considered in patients developing severe reactions at re-sting after VIT discontinuation and, as a speculation, patients with mastocytosis and HVA should be VIT-treated lifelong.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Conclusion There was no evidence of a reliable physician-rated response, ACQ-5 score, or lung function–based continuation rule. The added value of changes in blood eosinophils at week 16 over baseline was marginal. Initiation criteria for mepolizumab treatment provide the best method for assessing patient benefit from mepolizumab treatment, and treatment continuation should be reviewed on the basis of a predefined reduction in long-term exacerbation frequency and/or oral corticosteroid dose.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
We present the current evidence base, suggest resources, and highlight areas of current controversy that warrant further study.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 16 December 2017 Source:The Journal of Allergy and Clinical Immunology: In Practice Author(s): Kara B. McNamara, Brian C. Schroer
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Authors: Ostrom QT, Gittleman H, Stetson L, Virk S, Barnholtz-Sloan JS Abstract Gliomas are the most common primary intracranial neoplasms, which cause significant mortality and morbidity that is disproportionate to their relatively rare incidence. Many potential risk factors for glioma have been studied to date, but only few provide explanation for the number of brain tumor cases identified. The most significant findings include increased risk due to exposure to ionizing radiation and decreased risk with the history of allergy or atopic diseases. The potential effect of the cellular phone usage has been evaluated ...
Source: Progress in Neurological Surgery - Category: Neurosurgery Tags: Prog Neurol Surg Source Type: research
Conclusions Administering systematic premedication with corticosteroids and antihistamines had no significant effect on the effectiveness or safety of RDD in patients with confirmed hypersensitivity to paclitaxel in the study population. Moreover, these premedications can mask early signs of hypersensitivity and delay treatment. We believe that systematic premedication with these drugs for patients undergoing RDD should be carefully and individually assessed if their only purpose is to prevent breakthrough reactions during RDD.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Conclusions The use of the PAHA and subsequent PST is a safe, effective multidisciplinary intervention that facilitates the transition to β-lactam antibiotics. Our approach is unique in that it prioritizes patients based on the use of second-line antibiotics, and then applies an algorithm to determine eligibility for PST.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 7 December 2017 Source:The Journal of Allergy and Clinical Immunology: In Practice Author(s): Anna Postolova, Jonathan T. Bradley, David Parris, Janell Sherr, Sean A. McGhee, Joseph D. Hernandez
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
More News: Academia | Allergy | Allergy & Immunology | Respiratory Medicine | Training | Universities & Medical Training